TrialThe Journal of clinical endocrinology and metabolism2011

Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.

John B Buse et al.PubMed ↗Publisher ↗

No numbers read from the abstract.